id	sid	eid	entity	type
dti-2355	1	1	dti	ORG
dti-2355	1	2	2022	CARDINAL
dti-2355	1	3	16	CARDINAL
dti-2355	1	4	1-5	CARDINAL
dti-2355	1	5	1177-3928	CARDINAL
dti-2355	1	6	10.33393	CARDINAL
dti-2355	1	7	1177-3928	CARDINAL
dti-2355	1	8	2022	CARDINAL
dti-2355	2	1	4.0	CARDINAL
dti-2355	4	1	secukinumab	PERSON
dti-2355	4	2	martino	PERSON
dti-2355	4	3	poliambulatorio grottaglie	PERSON
dti-2355	4	4	grottaglie italy	PERSON
dti-2355	4	5	1% to 2.25%	PERCENT
dti-2355	6	1	secukinumab	PERSON
dti-2355	6	2	interleukin-17a	CARDINAL
dti-2355	6	3	il-17a	PRODUCT
dti-2355	7	1	72-year-old	DATE
dti-2355	7	2	two	CARDINAL
dti-2355	8	1	the first week	DATE
dti-2355	8	2	60 to 10	CARDINAL
dti-2355	8	3	1 month	DATE
dti-2355	9	1	secukinumab	PERSON
dti-2355	11	1	interleukin-17	DATE
dti-2355	11	2	palmoplantar hyperkeratosis	PERSON
dti-2355	11	3	secukinumab	PERSON
dti-2355	11	4	november 4, 2021	DATE
dti-2355	11	5	february 23	DATE
dti-2355	11	6	2022	CARDINAL
dti-2355	11	7	march 7	DATE
dti-2355	11	8	2022	CARDINAL
dti-2355	11	9	martino	PERSON
dti-2355	11	10	26	CARDINAL
dti-2355	11	11	74023	DATE
dti-2355	11	12	italy	GPE
dti-2355	11	13	2	CARDINAL
dti-2355	13	1	50-69 years	DATE
dti-2355	14	1	between 0.09%	PERCENT
dti-2355	14	2	11.4%	PERCENT
dti-2355	14	3	1	CARDINAL
dti-2355	14	4	approximately 3%	PERCENT
dti-2355	14	5	us	GPE
dti-2355	14	6	around 125 million	CARDINAL
dti-2355	14	7	0.5%	PERCENT
dti-2355	14	8	asian	NORP
dti-2355	14	9	8%	PERCENT
dti-2355	14	10	norway	GPE
dti-2355	15	1	3	CARDINAL
dti-2355	16	1	80%-90%	PERCENT
dti-2355	16	2	1	CARDINAL
dti-2355	17	1	2	CARDINAL
dti-2355	18	1	1	CARDINAL
dti-2355	19	1	2	CARDINAL
dti-2355	21	1	https://creativecommons.org/licenses/by-nc/4.0/legalcode	PRODUCT
dti-2355	21	2	management2	ORG
dti-2355	22	1	2022	CARDINAL
dti-2355	24	1	1177-3928	CARDINAL
dti-2355	24	2	first	ORDINAL
dti-2355	24	3	second	ORDINAL
dti-2355	24	4	2	CARDINAL
dti-2355	25	1	mirna	PERSON
dti-2355	26	1	2,3	CARDINAL
dti-2355	27	1	first	ORDINAL
dti-2355	27	2	3	CARDINAL
dti-2355	28	1	1% to 2.25%	PERCENT
dti-2355	29	1	over 75%	PERCENT
dti-2355	29	2	4	CARDINAL
dti-2355	29	3	5	CARDINAL
dti-2355	30	1	4	CARDINAL
dti-2355	31	1	ep	PERSON
dti-2355	31	2	5	CARDINAL
dti-2355	32	1	two	CARDINAL
dti-2355	33	1	first	ORDINAL
dti-2355	35	1	second	ORDINAL
dti-2355	35	2	6	CARDINAL
dti-2355	39	1	6	CARDINAL
dti-2355	41	1	the us national psoriasis foundation	ORG
dti-2355	41	2	2010	DATE
dti-2355	41	3	first	ORDINAL
dti-2355	41	4	acitretin	PERSON
dti-2355	43	1	second	ORDINAL
dti-2355	43	2	acitretin	PERSON
dti-2355	46	1	6	CARDINAL
dti-2355	47	1	secukinumab	PERSON
dti-2355	48	1	th1	GPE
dti-2355	48	2	th2	PERSON
dti-2355	48	3	th17	PRODUCT
dti-2355	48	4	th17	PRODUCT
dti-2355	48	5	7	CARDINAL
dti-2355	50	1	th17	PRODUCT
dti-2355	51	1	il-17a	PRODUCT
dti-2355	51	2	il-17ra	ORG
dti-2355	52	1	il-17a	PRODUCT
dti-2355	53	1	il-17a	PRODUCT
dti-2355	54	1	9	CARDINAL
dti-2355	55	1	il-17a	PRODUCT
dti-2355	56	1	one	CARDINAL
dti-2355	56	2	secukinumab	PERSON
dti-2355	56	3	il-17a	PRODUCT
dti-2355	56	4	10	CARDINAL
dti-2355	57	1	secukinumab	PERSON
dti-2355	57	2	il-17a	PRODUCT
dti-2355	58	1	11-14	CARDINAL
dti-2355	59	1	the european medicines	ORG
dti-2355	59	2	ema	ORG
dti-2355	59	3	15	CARDINAL
dti-2355	60	1	secukinumab	GPE
dti-2355	60	2	16	CARDINAL
dti-2355	61	1	il-17a	PRODUCT
dti-2355	62	1	il-17a	PRODUCT
dti-2355	62	2	2022	CARDINAL
dti-2355	62	3	16	CARDINAL
dti-2355	62	4	3	CARDINAL
dti-2355	62	5	2022	CARDINAL
dti-2355	63	1	16	CARDINAL
dti-2355	64	1	11	CARDINAL
dti-2355	65	1	two	CARDINAL
dti-2355	65	2	52-week	DATE
dti-2355	65	3	17	CARDINAL
dti-2355	66	1	738	CARDINAL
dti-2355	66	2	1,306	CARDINAL
dti-2355	67	1	secukinumab	PERSON
dti-2355	67	2	5 weeks	DATE
dti-2355	67	3	50 mg	QUANTITY
dti-2355	67	4	12 weeks	DATE
dti-2355	68	1	75	CARDINAL
dti-2355	68	2	week 12	DATE
dti-2355	68	3	81.6%	PERCENT
dti-2355	68	4	71.6%	PERCENT
dti-2355	68	5	300 mg	QUANTITY
dti-2355	68	6	150 mg	QUANTITY
dti-2355	68	7	secukinumab	GPE
dti-2355	68	8	4.5%	PERCENT
dti-2355	69	1	77.1%	PERCENT
dti-2355	69	2	300 mg	QUANTITY
dti-2355	69	3	secukinumab	GPE
dti-2355	69	4	67%	PERCENT
dti-2355	69	5	150 mg	QUANTITY
dti-2355	69	6	secukinumab	GPE
dti-2355	69	7	44%	PERCENT
dti-2355	69	8	only 4.9%	PERCENT
dti-2355	69	9	75	CARDINAL
dti-2355	69	10	week 12 (	DATE
dti-2355	69	11	17	CARDINAL
dti-2355	70	1	13	CARDINAL
dti-2355	70	2	300 mg	QUANTITY
dti-2355	70	3	weeks 0	DATE
dti-2355	70	4	1	DATE
dti-2355	70	5	2	DATE
dti-2355	70	6	3	DATE
dti-2355	70	7	4	CARDINAL
dti-2355	70	8	300 mg	QUANTITY
dti-2355	70	9	4 weeks	DATE
dti-2355	70	10	18	CARDINAL
dti-2355	71	1	secukinumab	PERSON
dti-2355	71	2	10/13	CARDINAL
dti-2355	71	3	77%	PERCENT
dti-2355	71	4	3 weeks	DATE
dti-2355	71	5	1.5-3 weeks	DATE
dti-2355	72	1	52-week	DATE
dti-2355	72	2	90	CARDINAL
dti-2355	72	3	10/13	CARDINAL
dti-2355	73	1	secukinumab	PERSON
dti-2355	73	2	18	CARDINAL
dti-2355	74	1	secukinumab drug	ORG
dti-2355	74	2	72-year-old	DATE
dti-2355	74	3	march 5, 2020	DATE
dti-2355	75	1	palmoplantar hyperkeratosis	PERSON
dti-2355	76	1	1a	CARDINAL
dti-2355	77	1	25 mg one	QUANTITY
dti-2355	77	2	8 days	DATE
dti-2355	77	3	half	CARDINAL
dti-2355	77	4	8 more days	DATE
dti-2355	79	1	march 16, 2020	DATE
dti-2355	79	2	100 mg	QUANTITY
dti-2355	79	3	july 2020	DATE
dti-2355	82	1	a few weeks	DATE
dti-2355	82	2	august 2020	DATE
dti-2355	84	1	september 1, 2020	DATE
dti-2355	84	2	300 mg	QUANTITY
dti-2355	84	3	two	CARDINAL
dti-2355	84	4	150 mg	QUANTITY
dti-2355	84	5	15	CARDINAL
dti-2355	85	1	1	CARDINAL
dti-2355	86	1	management4	PERSON
dti-2355	87	1	2022	CARDINAL
dti-2355	89	1	1177-3928	CARDINAL
dti-2355	91	1	first	ORDINAL
dti-2355	91	2	60	DATE
dti-2355	91	3	20	CARDINAL
dti-2355	91	4	fig	ORG
dti-2355	92	1	2a	CARDINAL
dti-2355	93	1	the end of february 2021	DATE
dti-2355	93	2	10	CARDINAL
dti-2355	94	1	january 2022	DATE
dti-2355	95	1	recent years	DATE
dti-2355	96	1	secukinumab	PERSON
dti-2355	97	1	weng et al	PERSON
dti-2355	97	2	19	CARDINAL
dti-2355	97	3	10	CARDINAL
dti-2355	97	4	secukinumab	PERSON
dti-2355	98	1	week 16	DATE
dti-2355	98	2	4/10	CARDINAL
dti-2355	98	3	7/10	CARDINAL
dti-2355	98	4	pasi 90	PRODUCT
dti-2355	98	5	pasi 75	ORG
dti-2355	98	6	19	CARDINAL
dti-2355	99	1	first	ORDINAL
dti-2355	100	1	60	DATE
dti-2355	100	2	20	CARDINAL
dti-2355	100	3	10	CARDINAL
dti-2355	100	4	6 months	DATE
dti-2355	102	1	enrica piras	PERSON
dti-2355	102	2	phd	PERSON
dti-2355	102	3	ray hill	PERSON
dti-2355	102	4	english	LANGUAGE
dti-2355	102	5	health publishing & services	ORG
dti-2355	102	6	srl	GPE
dti-2355	103	1	novartis farma	ORG
dti-2355	103	2	italy	GPE
dti-2355	105	1	contributions dr	PERSON
dti-2355	107	1	helsinki	ORG
dti-2355	112	1	1	CARDINAL
dti-2355	112	2	rajguru jp	PERSON
dti-2355	112	3	suri p	GPE
dti-2355	112	4	bhardwaj s	PERSON
dti-2355	114	1	2020	DATE
dti-2355	114	2	9(1):20	CARDINAL
dti-2355	115	1	crossref	ORG
dti-2355	115	2	2	CARDINAL
dti-2355	116	1	deng y	PERSON
dti-2355	116	2	chang c	PERSON
dti-2355	116	3	lu q.	PERSON
dti-2355	117	1	clin rev	PERSON
dti-2355	117	2	immunol	PERSON
dti-2355	118	1	2016	CARDINAL
dti-2355	119	1	50(3):377-389	CARDINAL
dti-2355	120	1	crossref pubmed fig	ORG
dti-2355	121	1	2	CARDINAL
dti-2355	121	2	secukinumab	PERSON
dti-2355	122	1	2022	CARDINAL
dti-2355	122	2	16	CARDINAL
dti-2355	122	3	5	CARDINAL
dti-2355	122	4	2022	CARDINAL
dti-2355	123	1	3	CARDINAL
dti-2355	124	1	armstrong aw	PERSON
dti-2355	127	1	4	CARDINAL
dti-2355	128	1	reynolds ka	PERSON
dti-2355	128	2	pithadia	PERSON
dti-2355	128	3	lee eb	PERSON
dti-2355	128	4	liao w	PERSON
dti-2355	128	5	wu jj	PERSON
dti-2355	130	1	j dermatolog	PERSON
dti-2355	131	1	2021;32(1):49-55	CARDINAL
dti-2355	132	1	5	CARDINAL
dti-2355	133	1	carrasquillo oy	ORG
dti-2355	134	1	j am	PERSON
dti-2355	135	1	2020;83(1):151-158	CARDINAL
dti-2355	136	1	6	CARDINAL
dti-2355	137	1	singh	GPE
dti-2355	137	2	lee km	PERSON
dti-2355	139	1	2016;6:93-104	CARDINAL
dti-2355	140	1	7	CARDINAL
dti-2355	141	1	fitch e	PERSON
dti-2355	141	2	harper e	PERSON
dti-2355	141	3	kurtz se	PERSON
dti-2355	141	4	blauvelt a. pathophysiology	PERSON
dti-2355	141	5	th17	PRODUCT
dti-2355	142	1	curr	PERSON
dti-2355	142	2	2007;9(6):461-467	DATE
dti-2355	143	1	8	CARDINAL
dti-2355	144	1	berg	PERSON
dti-2355	144	2	balogh ea	PERSON
dti-2355	144	3	ri	GPE
dti-2355	144	4	feldman sr	PERSON
dti-2355	147	1	2021	CARDINAL
dti-2355	147	2	13(3):201-216	CARDINAL
dti-2355	148	1	9	CARDINAL
dti-2355	148	2	krueger jg	PERSON
dti-2355	149	1	opin investig	PERSON
dti-2355	150	1	2013;22(8):993-1005	DATE
dti-2355	151	1	10	CARDINAL
dti-2355	152	1	wasilewska	PERSON
dti-2355	152	2	winiarska	ORG
dti-2355	152	3	l. interleukin-17	PERSON
dti-2355	155	1	2016;33(4):247-252	CARDINAL
dti-2355	156	1	11	CARDINAL
dti-2355	157	1	reich k	PERSON
dti-2355	157	2	warren	PERSON
dti-2355	157	3	coates lc	PERSON
dti-2355	157	4	di comite g. long-term	PERSON
dti-2355	159	1	2020;34(6):1161-1173	CARDINAL
dti-2355	160	1	12	CARDINAL
dti-2355	161	1	deodhar	ORG
dti-2355	161	2	mease pj	PERSON
dti-2355	161	3	mcinnes ib	PERSON
dti-2355	164	1	2019;21(1):111	CARDINAL
dti-2355	165	1	13	CARDINAL
dti-2355	166	1	gossec l	ORG
dti-2355	166	2	secukinumab	PERSON
dti-2355	166	3	3	CARDINAL
dti-2355	167	1	ann rheum dis	PERSON
dti-2355	168	1	2021;80(5):582-590	CARDINAL
dti-2355	169	1	crossref	ORG
dti-2355	169	2	14	CARDINAL
dti-2355	170	1	gaffney k	PERSON
dti-2355	170	2	secukinumab	PERSON
dti-2355	170	3	europe	LOC
dti-2355	172	1	2020;37(6):2865-2883	CARDINAL
dti-2355	173	1	15	CARDINAL
dti-2355	175	1	october 2021	DATE
dti-2355	176	1	16	CARDINAL
dti-2355	177	1	frieder j	ORG
dti-2355	177	2	a. secukinumab	PERSON
dti-2355	178	1	adv chronic dis	ORG
dti-2355	179	1	2018;9(1):5	CARDINAL
dti-2355	180	1	17	CARDINAL
dti-2355	181	1	langley rg	PERSON
dti-2355	181	2	lebwohl m	PERSON
dti-2355	182	1	secukinumab	PERSON
dti-2355	182	2	two	CARDINAL
dti-2355	182	3	3	CARDINAL
dti-2355	184	1	2014;371(4):326338	CARDINAL
dti-2355	185	1	crossref	ORG
dti-2355	185	2	18	CARDINAL
dti-2355	186	1	damiani g	PERSON
dti-2355	187	1	j clin med	PERSON
dti-2355	189	1	19	CARDINAL
dti-2355	190	1	weng hj	PERSON
dti-2355	190	2	wang ts	PERSON
dti-2355	190	3	tsai	PERSON
dti-2355	193	1	2018;178(6):1439-1440	DATE
dti-2355	194	1	https://www.ncbi.nlm.nih.gov/pubmed/28856115	ORG
dti-2355	194	2	https://www.ncbi.nlm.nih.gov/pubmed/32378070	CARDINAL
dti-2355	194	3	https://doi.org/10.1056/nejmoa1314258	PERSON